Aquinox is developing novel, small molecule therapeutics targeting SH2-containing inositol-5'-phosphatase 1 ("SHIP1") for the treatment of inflammatory disease and cancer. Its lead product candidate, AQX-1125, has demonstrated broad anti-inflammatory activity in vitro and in vivo, and has successfully completed three clinical trials with over 100 patients enrolled to date. Aquinox is currently investigating AQX-1125 in two Phase 2 clinical trials, one for exacerbations related to COPD, and one for BPS/IC.